Adenine phosphoribosyltransferase (APRT) catalyzes the synthesis of AMP from adenine and 5-phosphoribosyl-1-pyrophosphate. APRT deficiency (APRTD) results in an inability to utilize adenine, which is oxidized by xanthine dehydrogenase via 8-hydroxyadenine to 2,8-dihydroxyadenine. 2,8-Dihydroxyadenine is extremely insoluble, and its accumulation in the kidney results in crystalluria and the formation of urinary stones. Recently, a new approach for early diagnosis is expected worldwide, because of the increased recognition of delayed diagnosis. However, no specific approach has been proposed.
GC/MS-based metabolomics have been expected to facilitate the rapid, sensitive, and cost-effective chemical diagnosis of APRTD since 1997. We examined spot urine from four patients: 47 - and 61-year-old female siblings whose other sibling had died after 30 years of dialysis, a 66-year-old male with worsening kidney function, and a 29-year-old male with renal failure followed by kidney transplantation but with numerous crystals observed on post-operative day 3.
Within 1-2 days after sample arrival, all were found to have APRTD, because z- scores for the biomarkers were 6.1-8.9. Subsequent mutation analysis revealed APRT*J/J for the female and APRT*Q0/Q0 for males. Xanthine oxidase inhibitor prevented secondary 2,8-dihydroxyadenine nephrolithiasis after kidney transplantation.
We propose to modify the current diagnostic guidelines as follows: GC/MS-based metabolomics should be recommended at the start of the diagnosis, and also be recognized as a confirmative diagnosis if sample preparation, GC/MS measurement, and data analysis are performed in specialized laboratories. APRTD, xanthinuria type I-III, oxalosis type I-III, HPRT severe deficiency and, cystinuria are screened simultaneously at a cost of 15,000 JPY in our laboratory.
View full abstract